No registrations found.
ID
Source
Brief title
Health condition
psoriasis; artritis psoriatica; psoriatic arthritis; spondylartropathie; morbus bechterew; reactive artritis; reactive arthritis; inflammatory-bowel-disease-geassocieerde artritis; inflammatory-bowel-disease- associated arthritis; ankylosing spondylitis; spondyloarthritis.
Sponsors and support
Pfeizer deel-sponsor.
Intervention
Outcome measures
Primary outcome
- diagnose (artritis psoriatica versus psoriasis)
Secondary outcome
- ziekteactiviteit
Background summary
Objective: The primary objective is to identify molecular signatures that can serve as diagnostic and/or severity-of-disease markers for PsA and markers that can predict treatment response in patients with PsA. The secondary objective is to elucidate the underlying pathways in the development of PsA with the aim of discovering novel therapeutic targets.
Study design: Longitudinal observational study, where blood samples and clinical parameters will be prospectively collected for a maximum duration of five years per patient, and the data will be analysed using the systems biology approach.
Study population: Patients aged 18 - 75 years old with psoriasis (n=300), PsA (n=300), and a group of non-PsA spondyloarthritis (n=300, including ankylosing spondylitis, inflammatory bowel disease associated arthritis, reactive arthritis, or undifferentiated spondyloarthritis) in the out-patient clinics of the dermatology and rheumatology department.
Intervention: not applicable
Main study parameters/endpoints: Diagnosis, disease activity, and treatment response.
Study objective
Een "systeem biologische aanpak" kan nieuwe diagnostische markers en oorzakelijke immuunprocessen identificeren bij patiënten met artritis psoriatica.
Study design
1-3x per jaar
Intervention
Geen
University Medical Centre Utrecht <br>
P.O.Box 85090
E.F.A. Leijten
Lundlaan 6, 3508 GA, WKZ KC 02.084.2
[default]
The Netherlands
+31 (0)887553215
eleijte2@umcutrecht.nl
University Medical Centre Utrecht <br>
P.O.Box 85090
E.F.A. Leijten
Lundlaan 6, 3508 GA, WKZ KC 02.084.2
[default]
The Netherlands
+31 (0)887553215
eleijte2@umcutrecht.nl
Inclusion criteria
- The patient is age 18 - 75 years of age.
- For Population 1: a diagnosis of psoriasis made by a dermatologist
- For Population 2: a diagnosis of PsA according to CASPAR criteria and not yet treated with DMARDs or Biologicals
- For Population 3: a diagnosis of PsA according to CASPAR criteria and treated with DMARDs and/or Biologicals
- For Population 4: a diagnosis of SpA made by a rheumatologist, where the SpA is caused by an alternative disease than PsA, namely: ankylosing spondylitis (AS), inflammatory bowel disease associated arthritis, reactive arthritis, or undifferentiated spondyloarthritis.
Exclusion criteria
- The patient is age 17 years or younger
- The patient is age 76 years or older
- The patient has an alternative inflammatory rheumatological diagnosis (e.g. RA, gout, pseudo-gout).
- For Population 2: past or current treatment with DMARDs or Biologicals.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4508 |
| NTR-old | NTR4626 |
| Other | METC UMC Utrecht : 13-696/M |